# The Misuse of Drugs Regulations 2001, Paragraph 2


Any compound (not being Trilostane or a compound for the time being specified in paragraph 1 of this Part of this Schedule) structurally derived from 17-hydroxyandrostan-3-one or from 17-hydroxyestran-3-one by modification in any of the following ways, that is to say -
(a) by further substitution at position 17 by a methyl or ethyl group;
(b) by substitution to any extent at one or more of positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position;
(c) by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring;
(d) by fusion of ring A with a heterocyclic system.

---
Source: https://www.legislation.gov.uk/uksi/2001/3998/schedule/4/part/II/paragraph/2 (the official version)
Page: https://openlegislation.uk/misuse-of-drugs-regulations-2001/schedule-4/part-II/paragraph-2
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.